AIチャット
ELAB のデータを読み込んでいます。初回のため数秒かかります。

PMGC Holdings Inc.

ELAB · NasdaqCM · USD

2.81 -0.02 (-0.71%)

終値時点: Oct 20, 2026, 4:00 PM EDT

出来高
4.12K

PMGC Holdings Inc.(ELAB)の株価・分析・データ

間隔:1D
ローソク足とシグナルを読み込み中…

本源的価値

バリュエーションモデルは Pro の機能です。サインインまたはアップグレードすると分析全体を表示できます。

プランを見る →

アナリスト予想

株価予想 →

アナリスト予測は利用できません

12か月目標株価 · アナリストn/a人

アナリストのコンセンサス: n/a

無料の概要を表示しています

無料アカウントを作成して、この銘柄に関するさらに詳しいリサーチをご覧ください。

業績

財務情報を見る →

読み込み中...

最新決算

実績予想との差前年比
売上高—n/an/a
EPS(TTM)—n/an/a

次回決算

決算の詳細を見る →

事業指標

買気配
2.41
純利益(TTM)
-13.6M
-0.27
-1748.36
n/a
n/a
PBR(TTM)
0.10
PSR(TTM)
0.88
決算発表日
n/a
売気配
3.35
出来高
4,116
平均出来高(20日)
50,813
始値
2.87
前日終値
2.83
当日レンジ
2.75 - 2.87
52週レンジ
2.58 - 1680.00
配当
n/a
権利落ち日
n/a

PMGC Holdings Inc.について

企業情報を見る →
PMGC Holdings Inc., doing business as NorthStrive Holdings, Inc, a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California. Biotechnology · Healthcare

PMGC Holdings Inc., doing business as NorthStrive Holdings, Inc, a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

セクター Healthcare
IPO日 Nov 21, 2023
従業員数 32
上場取引所 NasdaqCM
ティッカー ELAB
ウェブサイト https://pmgcholdings.com